Bleda et al., in an in vitro experiment involving individuals with peripheral arterial disease treated with or without simvastatin, found that the treatment of human arterial endothelial cells with plasma from peripheral arterial disease patients on simvastatin therapy could ameliorate NLRP1 inflammasome expression in the setting of peripheral arterial disease [86]. Here, NLRP1 is linked to peripheral arterial disease.